ClinicalTrials.gg
TerminatedNCT03792841Updated Nov 10, 2026Results posted

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

A Phase 1 interventional study of acapatamab and Pembrolizumab in Metastatic Castration-resistant Prostate Cancer and Prostate Cancer, sponsored by Amgen. Terminated at 30 sites in 10 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

How we know · 12 judgments · 2 readings being read again

Why this study was terminated
Sponsor Decision
Updated Nov 10, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
212
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Prostatic Neoplasms by Amgen — 4 open to participants now, 7 under way, 2 of them phase 3. Prostatic Neoplasms · Amgen.

Enrollment
8th of 21
212 · median 64
Started
2019
the only one that year
Phase 1
9 of 23
3 open now
Registered
14th of 23
by date

Among the 23 studies in Prostatic Neoplasms by Amgen, this one is the 8th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2019, is one of 9 in phase 1, and was the 14th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 23 studies in Prostatic Neoplasms by Amgen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prostatic Neoplasms by Amgen, or all of them as a file.
02

Study summary

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant prostate cancer, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

Read the detailed description

This is a phase I, first-in-human study to evaluate the safety and tolerability of acapatamab; a half-life extended (HLE) bispecific T-cell engager (BiTE®) construct, alone and in combination with pembrolizumab, etanercept prophylaxis and cytochrome P450 (CYP) phenotyping cocktail in subjects with metastatic castration-resistant prostate cancer.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer
  • Prostate Cancer

Browse trials for

Keywords

  • acapatamab
  • HLE-BiTE®
  • mCRPC
  • Metastatic Castration-resistant Prostate Cancer
  • Prostate cancer
  • PSMA
  • BiTE®
  • Bispecific T-Cell engager
  • Immunotherapy
  • Immuno-oncology
  • Immunooncology
  • Solid tumor
  • PSMA Targeted Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

All Parts

Inclusion criteria

Inclusion Criteria:

  • Subject has provided prior to initiation of any study specific activities/procedures
  • Subjects with or cytologically confirmed mCRPC who are to a novel antiandrogen therapy (abiraterone, enzalutamide, and/or apalutamide) and have failed at least 1 (but not more than 2) taxane regimens (or who are deemed medically unsuitable to be treated with a taxane regimen or have actively refused treatment with a taxane regimen). Progression on novel antiandrogen therapy may have occurred in the non- CRPC setting
  • Subjects must have undergone bilateral orchiectomy or must be on continuous ADT with a gonadotropin releasing hormone (GnRH) agonist or antagonist
  • Total serum testosterone \</= 50 ng/dL or 1.7 nmol/L
  • Evidence of progressive disease, defined as 1 or more PCWG3 criteria:
  • PSA level >/= 1 ng/mL that has increased on at least 2 successive occasions at least 1 week apart
  • nodal or visceral progression as defined by 1.1 with PCGW3 modifications
  • appearance of 2 or more new lesions in bone scan
  • (ECOG) performance status of 0 - 1
  • >/= 6months

Exclusion criteria

Exclusion Criteria:

  • Any anticancer therapy or immunotherapy within 4 weeks of start of first dose, not including luteinizing hormone-releasing hormone agonist (LHRH)/GnRH analogue (agonist/antagonist). Subjects on a stable bisophosphonate or denosumab regimen for >/= 30 days prior to randomization are eligible
  • Prior PSMA-targeted therapy (subjects on prior therapy may be eligible if discussed with Amgen medical monitor prior to enrollment)
  • Central nervous system (CNS) , , or spinal cord compression
  • Active disease or any other diseases requiring therapy while on study
  • Needing chronic systemic therapy (prednisone > 10 mg per day or equivalent) or any other immunosuppressive therapies (including anti-tumor necrosis factor alpha [TNF alpha] therapies) unless stopped 7 days prior to start of first dose
  • Myocardial infarction, unstable angina, cardiac arrhythmia requiring medication, and/or symptomatic congestive heart failure ( > class II) within 12 months of first dose of acapatamab

Part 2 only:

  • Subjects on a prior or PD-L1 inhibitor who experienced a Grade 3 or higher immune-related adverse event prior to first day of dosing
  • History or evidence of interstitial lung disease or active, non-infectious pneumonitis

Part 3 only:

- Evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of product

Part 6 only:

Subjects are excluded from this cohort if any of the following additional criteria apply:

  • Subjects taking strong OAT3 inhibitors (eg, probenecid) or adjust the dosing to 1 mg PO QD.
  • Subjects with latent or active tuberculosis at screening
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
212 participants (actual)

Study arms

  • Experimental
    Part 1 Dose-exploration: acapatamab treatment

    Part 1 dose-exploration: acapatamab is administered intravenously. The dose-exploration phase of the study will estimate the MTD of acapatamab. RP2D may be identified based on emerging safety, efficacy, and pharmacodynamic data prior to reaching an MTD.

    Drug: acapatamab

  • Experimental
    Part 1 Dose-expansion: acapatamab treatment

    Part 1 dose-expansion: acapatamab is administered intravenously at the MTD/RP2D.

    Drug: acapatamab

  • Experimental
    Part 2: acapatamab + Pembrolizumab

    Part 2: acapatamab is administered intravenously at the MTD/RP2D. Pembrolizumab will be administered intravenously.

    Drug: acapatamab · Drug: Pembrolizumab

  • Experimental
    Part 3: acapatamab + Etanercept Prophylaxis

    Part 3: acapatamab is administered intravenously at RP2D/MTD levels. Etanercept will be administered subcutaneously in cycle 1 only.

    Drug: acapatamab · Drug: Etanercept

  • Experimental
    Part 4: acapatamab 24 Hour Monitoring

    Part 4: acapatamab is administered intravenously at RP2D/MTD with 24-hour monitoring.

    Drug: acapatamab

  • Experimental
    Part 5: acapatamab Outpatient Cohort

    Part 5: acapatamab is administered intravenously at RP2D/MTD in an outpatient setting with 8-hour monitoring.

    Drug: acapatamab

  • Experimental
    Part 6: acapatamab + Cytochrome P450 (CYP) Cocktail Drug Interaction

    Part 6: acapatamab is administered intravenously at RP2D/MTD. A CYP phenotyping cocktail will be administered orally.

    Drug: acapatamab · Drug: Cytochrome P450 (CYP) Cocktail

Interventions

  • Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer

    Also known as: PSMA Targeted Therapy

  • Combined with acapatamab for investigational treatment of mCRPC

    Also known as: PD-1 inhibitor

  • Prophylaxis for acapatamab-related cytokine release syndrome.

    Also known as: TNF-alpha inhibitor

  • DrugCytochrome P450 (CYP) Cocktail

    Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma

    Also known as: Cooperstown 5+1 CYP phenotyping cocktail

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Dose Limiting Toxicity (DLT)- Parts 1 and 2

    DLTs are defined as any adverse event with an onset within first 28 days following first dose of AMG 160 monotherapy (Part 1) or in combination with pembrolizumab (Part 2) with any of the following criteria unless clearly attributable to causes other than AMG 160 treatment: • grade 5 toxicity (eg, death not due to disease progression)

    Time frame: Day 1 to 28 of Cycle 1 (length of cycle is 28 days)

  2. Number of Participants With Treatment Emergent Adverse Events- Parts 1, 2, 3, 4, and 5

    A treatment-emergent adverse event is one that occurs on or after the first dose of study treatment and up to 30 days after the last dose. Adverse events were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any clinically significant changes in vital signs, electrocardiograms, and clinical laboratory tests were recorded as adverse events.

    Time frame: Up to 30 days after the last dose of study drug, or start of new anti-cancer therapy, whichever occurs first

Secondary outcomes

  1. Objective Response (OR) Rate- Parts 1, 2, 3, 4, and 5

    OR was defined as a partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, confirmed by a repeat assessment at least 4 weeks later. Participants who did not experience a PR/CR or did not have any follow-up tumor assessments were regarded as non-responders.

    Time frame: Up to 3 years

  2. Prostate-specific Antigen (PSA) Response- Parts 1, 2, 3, 4, and 5

    A PSA response (PSA 30) is defined as a ≥ 30% reduction from the baseline PSA, (PSA 50) is defined as a ≥ 50% reduction from the baseline PSA, (PSA 70) is defined as a ≥ 70% reduction from the baseline PSA, and (PSA 90) is defined as a ≥ 90% reduction from the baseline PSA. PSA response must be confirmed by a second consecutive value ≥ 3 weeks later.

    Time frame: Up to 3 years

  3. Duration of Response (DOR)-RECIST 1.1- Parts 1, 2, 3, 4, and 5

    DOR is defined as the time from the date of an initial objective response per RECIST 1.1 to the earlier of progression or death. Participants who had not ended their response at the time of analysis had DOR censored at their last evaluable tumor assessment.

    Time frame: Up to 3 years

  4. Duration of PSA Response- Parts 1, 2, 3, 4, and 5

    PSA DOR is defined as the time from the date of an initial PSA response (PSA 50) to the earlier of PSA progression or death. Subjects who have not ended their response at the time of analysis will have PSA DOR censored on the date of their last PSA measurement. This endpoint only applies to subjects with a PSA response (PSA 50).

    Time frame: Up to 3 years

  5. Percentage of Participants With 68Gallium (68Ga)-Prostate-specific Membrane Antigen (PSMA) Response Parts 1, 2, and 3

    A Gallium PSMA-11 response is a ≥50% reduction from baseline in the maximum standardized uptake value (SUV) using 68Gallium (68Ga)-prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT).

    Time frame: Up to 3 years

  6. Percentage of Participants With F-fluorodeoxyglucose (FDG) Response- Parts 1, 2, and 3

    A FDG PET response is a ≥50% reduction from baseline in the maximum SUV using 18F-FDG PET/CT.

    Time frame: Up to 3 years

  7. Time to Progression (Radiographic)- Parts 1, 2, 3, 4, and 5

    Time to radiographic progression is defined as the time from study Day 1 until the first documentation of radiographic disease progression in the absence of subsequent anticancer therapy. Time to radiographic progression will be censored at the last evaluable post-baseline tumor assessment prior to subsequent anti-cancer therapy; otherwise, at study Day 1.

    Time frame: Up to 3 years

  8. Time to Progression (PSA)- Parts 1, 2, 3, 4, and 5

    Time to PSA progression is defined as the interval from study Day 1 to PSA progression; otherwise, time to PSA progression is censored on the date of the last PSA measurement. If a participant has no baseline or no post-baseline PSA measurement, time to PSA progression will be censored at study Day 1.

    Time frame: Up to 3 years

  9. Progression Free Survival (Radiographic)- Parts 1, 2, 3, 4, and 5

    Radiographic progression free survival (rPFS) is defined as the interval from study day 1 to the earlier of a radiographic progression or death from any cause; otherwise, rPFS is censored at the last evaluable tumor assessment date. If a subject has no post-baseline radiographic tumor assessment and a vital status of alive or unknown, rPFS will be censored at study day 1.

    Time frame: Up to 3 years

  10. Progression Free Survival (PSA)- Parts 1, 2, 3, 4, and 5

    PSA PFS is defined as the interval from study day 1 to the earlier of a PSA progression or death from any cause; otherwise, PSA PFS is censored on the date of the last PSA measurement. If a subject has no baseline or no post-baseline PSA measurement and a vital status of alive or unknown, PSA PFS will be censored at study day 1.

    Time frame: Up to 3 years

  11. Overall Survival- Parts 1, 2, 3, 4, and 5

    Overall survival (OS) is defined as the time from the date of study Day 1 until death due to any cause.

    Time frame: Up to 3 years

  12. Percentage of Participants With Circulating Tumor Cell Response (CTC0)- Parts 1, 2, 3, 4, and 5

    CTC0 is defined as reduction of CTCs \> 0 to 0 at any post-baseline measurement. CTC0 response is applicable only for participants with baseline CTC \> 0.

    Time frame: Up to 3 years

  13. Percentage of Participants With CTC Conversion- Parts 1, 2, 3, 4, and 5

    CTC conversion is defined as ≥ 5 CTCs/7.5 mL blood to ≤ 4 CTCs/7.5 mL blood at any post-baseline measurement. CTC conversion is applicable only for subjects with baseline CTC ≥ 5..

    Time frame: Up to 3 years

  14. Time to Symptomatic Skeletal Events (SSE)- Parts 1, 2, 3, 4, and 5

    Time to SSE is defined as time from study day 1 to the first SSE. Otherwise, SSE is censored at the last dose date of AMG 160 or pembrolizumab or end of safety follow up date, whichever is later.

    Time frame: Up to 3 years

  15. Maximum Observed Concentration (Cmax) of AMG 160 - Parts 1, 2, and 3

    Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of pharmacokinetic (PK) parameters. Concentrations below the lower limit of quantification (LLOQ) (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

    Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)

  16. Time to Cmax (Tmax) of AMG 160- Parts 1, 2, and 3

    Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. Actual time post dose was used for calculations. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

    Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 696 hours)

  17. Minimum Serum Concentration (Cmin) of AMG 160- Parts 1, 2, and 3

    Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

    Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))

  18. Area Under the Concentration-time Curve (AUC) From Time 0 to Last Quantifiable Concentration (AUClast) of AMG 160- Parts 1, 2, and 3

    Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

    Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))

  19. AUC Over the Dosing Interval (AUCtau)- Parts 1, 2, and 3

    Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

    Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)

  20. Terminal Half-life (t1/2,z) of AMG 160- Parts 1, 2, and 3

    Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

    Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)

07

Results

Posted Nov 10, 2026

Participant flow

Participants were enrolled from 05 Feb 2019 to 29 Jun 2023 at 26 centers in Australia, Austria, Belgium, Canada, France, Japan, the Netherlands, Singapore, and the United States.

Participant flow — Overall Study
MilestonePart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy Dose Expansion (DE) (0.3 mg)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With Cytokine Release Syndrome (CRS) Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
Started341364443464321446475663573332623
Completed001010000000000000001000000020
Not completed340354443464321446475563573332423
Withdrew: Withdrawal by subject000011000011000002015000201153
Withdrew: Sponsor decision0000010000201102100110002120078
Withdrew: Lost to follow-up000000010000000000000000001011
Withdrew: Death340342433433211234454063341121111

Outcome measures

PrimaryNumber of Participants With a Dose Limiting Toxicity (DLT)- Parts 1 and 2

DLTs are defined as any adverse event with an onset within first 28 days following first dose of AMG 160 monotherapy (Part 1) or in combination with pembrolizumab (Part 2) with any of the following criteria unless clearly attributable to causes other than AMG 160 treatment: • grade 5 toxicity (eg, death not due to disease progression)

Time frame:
Day 1 to 28 of Cycle 1 (length of cycle is 28 days)
Reported as:
Count of participants · Participants
Number of Participants With a Dose Limiting Toxicity (DLT)- Parts 1 and 2
ParticipantsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D
Number of Participants With a Dose Limiting Toxicity (DLT)- Parts 1 and 200100010100101121200401010
SecondaryObjective Response (OR) Rate- Parts 1, 2, 3, 4, and 5

OR was defined as a partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, confirmed by a repeat assessment at least 4 weeks later. Participants who did not experience a PR/CR or did not have any follow-up tumor assessments were regarded as non-responders.

Time frame:
Up to 3 years
Reported as:
Number · Percentage of Participants
Objective Response (OR) Rate- Parts 1, 2, 3, 4, and 5
Percentage of ParticipantsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
Objective Response (OR) Rate- Parts 1, 2, 3, 4, and 50 (0.00 to 84.19)0 (0.00 to 84.19)—100 (2.50 to 100.00)20 (0.51 to 71.64)0 (0.00 to 84.19)0 (0.00 to 84.19)0 (0.00 to 70.76)0 (0.00 to 97.50)0 (0.00 to 70.76)0 (0.00 to 84.19)0 (0.00 to 97.50)50 (1.26 to 98.74)0 (0.00 to 97.50)—100 (2.50 to 100.00)50 (1.26 to 98.74)0 (0.00 to 70.76)0 (0.00 to 70.76)0 (0.00 to 70.76)7.4 (0.91 to 24.29)0 (0.00 to 52.18)0 (0.00 to 70.76)0 (0.00 to 84.19)25 (0.63 to 80.59)0 (0.00 to 84.19)0 (0.00 to 84.19)33.3 (0.84 to 90.57)16.7 (2.09 to 48.41)0 (0.00 to 30.85)
SecondaryProstate-specific Antigen (PSA) Response- Parts 1, 2, 3, 4, and 5

A PSA response (PSA 30) is defined as a ≥ 30% reduction from the baseline PSA, (PSA 50) is defined as a ≥ 50% reduction from the baseline PSA, (PSA 70) is defined as a ≥ 70% reduction from the baseline PSA, and (PSA 90) is defined as a ≥ 90% reduction from the baseline PSA. PSA response must be confirmed by a second consecutive value ≥ 3 weeks later.

Time frame:
Up to 3 years
Reported as:
Number · Percentage of Participants
Prostate-specific Antigen (PSA) Response- Parts 1, 2, 3, 4, and 5
Percentage of ParticipantsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
PSA 300 (0.00 to 70.76)0 (0.00 to 60.64)100 (2.50 to 100.00)33.3 (0.84 to 90.57)16.7 (0.42 to 64.12)50 (6.76 to 93.24)50 (6.76 to 93.24)25 (0.63 to 80.59)33.3 (0.84 to 90.57)25 (0.63 to 80.59)20 (0.51 to 71.64)50 (6.76 to 93.24)66.7 (9.43 to 99.16)100 (15.81 to 100.00)100 (2.50 to 100.00)100 (39.76 to 100.00)75 (19.41 to 99.37)16.7 (0.42 to 64.12)50 (6.76 to 93.24)57.1 (18.41 to 90.10)39.3 (26.50 to 53.25)16.7 (0.42 to 64.12)33.3 (0.84 to 90.57)40 (5.27 to 85.34)14.3 (0.36 to 57.87)0 (0.00 to 70.76)33.3 (0.84 to 90.57)33.3 (0.84 to 90.57)38.5 (20.23 to 59.43)38.1 (18.11 to 64.56)
PSA 500 (0.00 to 70.76)0 (0.00 to 60.64)100 (2.50 to 100.00)0 (0.00 to 70.76)16.7 (0.42 to 64.12)25 (0.63 to 80.59)25 (0.63 to 80.59)0 (0.00 to 60.24)33.3 (0.84 to 90.57)25 (0.63 to 80.59)20 (0.51 to 71.64)50 (6.76 to 93.24)66.7 (9.43 to 99.16)100 (15.81 to 100.00)100 (2.50 to 100.00)75 (19.41 to 99.37)75 (19.41 to 99.37)16.7 (0.42 to 64.12)25 (0.63 to 80.59)42.9 (9.90 to 81.59)30.4 (18.78 to 44.10)16.7 (0.42 to 64.12)0 (0.00 to 70.76)20 (0.51 to 71.64)14.3 (0.36 to 57.87)0 (0.00 to 70.76)33.3 (0.84 to 90.57)33.3 (0.84 to 90.57)34.6 (17.21 to 55.67)19.0 (5.45 to 41.91)
PSA 700 (0.00 to 70.76)0 (0.00 to 60.64)0 (0.00 to 97.50)0 (0.00 to 70.76)16.7 (0.42 to 64.12)0 (0.00 to 60.24)25 (0.63 to 80.59)0 (0.00 to 60.24)33.3 (0.84 to 90.57)0 (0.00 to 60.24)20 (0.51 to 71.64)50 (6.76 to 93.24)33.3 (0.84 to 90.57)100 (15.81 to 100.00)100 (2.50 to 100.00)75 (19.41 to 99.37)50 (6.76 to 93.24)16.7 (0.42 to 64.12)0 (0.00 to 60.24)14.3 (0.36 to 57.87)21.4 (11.59 to 34.44)16.7 (0.42 to 64.12)0 (0.00 to 70.76)20 (0.51 to 71.64)0 (0.00 to 40.96)0 (0.00 to 70.76)33.3 (0.84 to 90.57)33.3 (0.84 to 90.57)30.8 (14.33 to 51.79)19.0 (5.45 to 41.91)
PSA 900 (0.00 to 70.76)0 (0.00 to 60.64)0 (0.00 to 97.50)0 (0.00 to 70.76)16.7 (0.42 to 64.12)0 (0.00 to 60.24)0 (0.00 to 60.24)0 (0.00 to 60.24)33.3 (0.84 to 90.57)0 (0.00 to 60.24)0 (0.00 to 52.18)25 (0.63 to 93.24)33.3 (0.84 to 80.59)100 (15.81 to 100.00)0 (0.00 to 97.50)50 (6.76 to 93.24)25 (0.63 to 80.59)16.7 (0.42 to 64.12)0 (0.00 to 60.24)0 (0.00 to 40.96)5.4 (1.12 to 14.87)0 (0.00 to 45.93)0 (0.00 to 70.76)20 (0.51 to 71.64)0 (0.00 to 40.96)0 (0.00 to 70.76)0 (0.00 to 70.76)0 (0.00 to 70.76)15.4 (4.36 to 34.87)9.5 (1.17 to 30.83)
SecondaryDuration of Response (DOR)-RECIST 1.1- Parts 1, 2, 3, 4, and 5

DOR is defined as the time from the date of an initial objective response per RECIST 1.1 to the earlier of progression or death. Participants who had not ended their response at the time of analysis had DOR censored at their last evaluable tumor assessment.

Time frame:
Up to 3 years
Reported as:
Median · Months
Duration of Response (DOR)-RECIST 1.1- Parts 1, 2, 3, 4, and 5
MonthsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
Duration of Response (DOR)-RECIST 1.1- Parts 1, 2, 3, 4, and 5———5.62 (NA to NA)8.57 (NA to NA)———————NA (NA to NA)——NA (NA to NA)NA (NA to NA)———5.19 (3.81 to NA)———NA (NA to NA)——NA (NA to NA)NA (NA to NA)—
SecondaryDuration of PSA Response- Parts 1, 2, 3, 4, and 5

PSA DOR is defined as the time from the date of an initial PSA response (PSA 50) to the earlier of PSA progression or death. Subjects who have not ended their response at the time of analysis will have PSA DOR censored on the date of their last PSA measurement. This endpoint only applies to subjects with a PSA response (PSA 50).

Time frame:
Up to 3 years
Reported as:
Median · Months
Duration of PSA Response- Parts 1, 2, 3, 4, and 5
MonthsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
Duration of PSA Response- Parts 1, 2, 3, 4, and 5——1.87 (NA to NA)—25.33 (NA to NA)2.14 (NA to NA)2.79 (NA to NA)—0.99 (NA to NA)1.87 (NA to NA)2.83 (NA to NA)2.79 (1.87 to NA)3.30 (1.97 to NA)5.03 (4.53 to NA)0.99 (NA to NA)2.20 (0.99 to NA)1.84 (0.99 to NA)1.87 (NA to NA)1.91 (NA to NA)1.15 (0.95 to NA)1.91 (0.95 to 3.71)4.96 (NA to NA)—4.86 (NA to NA)0.95 (NA to NA)—1.81 (NA to NA)1.87 (NA to NA)2.79 (0.95 to 7.66)3.29 (2.23 to NA)
SecondaryPercentage of Participants With 68Gallium (68Ga)-Prostate-specific Membrane Antigen (PSMA) Response Parts 1, 2, and 3

A Gallium PSMA-11 response is a ≥50% reduction from baseline in the maximum standardized uptake value (SUV) using 68Gallium (68Ga)-prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT).

Time frame:
Up to 3 years
Reported as:
Number · Percentage of Participants
Percentage of Participants With 68Gallium (68Ga)-Prostate-specific Membrane Antigen (PSMA) Response Parts 1, 2, and 3
Percentage of ParticipantsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf
Percentage of Participants With 68Gallium (68Ga)-Prostate-specific Membrane Antigen (PSMA) Response Parts 1, 2, and 30 (0.00 to 84.19)0 (0.00 to 97.50)0 (0.00 to 97.50)50 (1.26 to 98.74)33.3 (0.84 to 90.57)0 (0.00 to 84.19)0 (NA to NA)50 (1.26 to 98.74)0 (0.00 to 97.50)0 (0.00 to 60.24)0 (0.00 to 45.93)0 (0.00 to 97.50)33.3 (0.84 to 90.57)50 (1.26 to 98.74)0 (NA to NA)0 (NA to NA)50 (1.26 to 98.74)0 (0.00 to 97.50)0 (NA to NA)0 (NA to NA)29.5 (16.76 to 45.20)33.3 (4.33 to 77.72)0 (0.00 to 97.50)33.3 (0.84 to 90.57)25 (0.63 to 80.59)0 (0.00 to 84.19)0 (0.00 to 70.76)0 (0.00 to 70.76)
SecondaryPercentage of Participants With F-fluorodeoxyglucose (FDG) Response- Parts 1, 2, and 3

A FDG PET response is a ≥50% reduction from baseline in the maximum SUV using 18F-FDG PET/CT.

Time frame:
Up to 3 years
Reported as:
Number · Percentage of Participants
Percentage of Participants With F-fluorodeoxyglucose (FDG) Response- Parts 1, 2, and 3
Percentage of ParticipantsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf
Percentage of Participants With F-fluorodeoxyglucose (FDG) Response- Parts 1, 2, and 30 (0.00 to 84.19)0 (0.00 to 84.19)0 (0.00 to 97.50)0 (0.00 to 84.19)0 (0.00 to 60.24)0 (0.00 to 84.19)0 (0.00 to 97.50)0 (0.00 to 97.50)0 (0.00 to 97.50)0 (0.00 to 60.24)0 (0.00 to 45.93)0 (0.00 to 97.50)0 (0.00 to 70.76)0 (0.00 to 84.19)0 (NA to NA)0 (NA to NA)0 (0.00 to 84.19)0 (0.00 to 97.50)0 (NA to NA)0 (NA to NA)7.7 (1.62 to 20.87)0 (0.00 to 52.18)0 (0.00 to 97.50)0 (0.00 to 70.76)0 (0.00 to 45.93)0 (0.00 to 84.19)0 (0.00 to 70.76)0 (0.00 to 70.76)
SecondaryTime to Progression (Radiographic)- Parts 1, 2, 3, 4, and 5

Time to radiographic progression is defined as the time from study Day 1 until the first documentation of radiographic disease progression in the absence of subsequent anticancer therapy. Time to radiographic progression will be censored at the last evaluable post-baseline tumor assessment prior to subsequent anti-cancer therapy; otherwise, at study Day 1.

Time frame:
Up to 3 years
Reported as:
Median · Months
Time to Progression (Radiographic)- Parts 1, 2, 3, 4, and 5
MonthsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
Time to Progression (Radiographic)- Parts 1, 2, 3, 4, and 5NA (1.74 to NA)5.01 (1.64 to NA)NA (NA to NA)13.77 (NA to NA)2.07 (0.49 to NA)3.81 (1.64 to NA)2.83 (1.87 to NA)2.69 (1.58 to NA)3.53 (1.71 to NA)2.00 (1.71 to NA)10.84 (0.89 to NA)NA (1.87 to NA)5.95 (3.75 to NA)8.38 (NA to NA)NA (NA to NA)8.34 (NA to NA)NA (NA to NA)5.19 (1.87 to NA)2.74 (0.46 to NA)3.66 (1.71 to NA)3.58 (1.97 to 5.39)2.07 (1.81 to NA)1.71 (1.64 to NA)8.18 (1.84 to NA)NA (1.94 to NA)1.68 (NA to NA)2.33 (1.15 to NA)1.81 (1.64 to NA)5.39 (3.68 to 11.07)5.65 (2.33 to 8.57)
SecondaryTime to Progression (PSA)- Parts 1, 2, 3, 4, and 5

Time to PSA progression is defined as the interval from study Day 1 to PSA progression; otherwise, time to PSA progression is censored on the date of the last PSA measurement. If a participant has no baseline or no post-baseline PSA measurement, time to PSA progression will be censored at study Day 1.

Time frame:
Up to 3 years
Reported as:
Median · Months
Time to Progression (PSA)- Parts 1, 2, 3, 4, and 5
MonthsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
Time to Progression (PSA)- Parts 1, 2, 3, 4, and 52.79 (NA to NA)4.37 (2.53 to NA)2.79 (NA to NA)3.48 (3.02 to NA)3.14 (2.10 to NA)2.23 (1.87 to NA)3.71 (2.14 to NA)2.48 (1.84 to NA)NA (1.87 to NA)3.02 (2.99 to NA)3.68 (3.06 to NA)4.83 (3.02 to NA)3.02 (2.99 to NA)6.70 (4.99 to NA)2.10 (NA to NA)3.48 (2.14 to NA)3.70 (2.10 to NA)3.06 (1.22 to NA)2.07 (NA to NA)2.99 (2.10 to NA)3.02 (3.02 to 4.86)NA (2.07 to NA)1.87 (1.51 to NA)6.01 (2.63 to NA)2.10 (2.10 to NA)NA (NA to NA)2.72 (2.40 to NA)2.10 (NA to NA)3.94 (2.14 to 5.55)3.02 (2.10 to 6.70)
SecondaryProgression Free Survival (Radiographic)- Parts 1, 2, 3, 4, and 5

Radiographic progression free survival (rPFS) is defined as the interval from study day 1 to the earlier of a radiographic progression or death from any cause; otherwise, rPFS is censored at the last evaluable tumor assessment date. If a subject has no post-baseline radiographic tumor assessment and a vital status of alive or unknown, rPFS will be censored at study day 1.

Time frame:
Up to 3 years
Reported as:
Median · Months
Progression Free Survival (Radiographic)- Parts 1, 2, 3, 4, and 5
MonthsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
Progression Free Survival (Radiographic)- Parts 1, 2, 3, 4, and 51.74 (1.41 to NA)5.01 (1.64 to NA)NA (NA to NA)11.43 (1.45 to NA)2.07 (0.49 to NA)4.35 (1.64 to NA)2.83 (1.87 to NA)2.69 (1.58 to NA)2.23 (1.71 to NA)2.00 (1.71 to NA)10.84 (0.89 to NA)NA (1.87 to NA)5.95 (3.75 to NA)8.38 (NA to NA)NA (NA to NA)8.34 (NA to NA)NA (6.90 to NA)4.47 (1.87 to NA)2.74 (0.46 to NA)3.66 (1.71 to NA)3.71 (1.97 to 5.36)2.89 (1.81 to NA)1.71 (1.64 to NA)8.18 (1.84 to NA)NA (1.94 to NA)0.89 (0.10 to NA)2.40 (1.15 to NA)1.81 (1.64 to NA)5.39 (3.61 to 11.07)5.62 (3.38 to 8.57)
SecondaryProgression Free Survival (PSA)- Parts 1, 2, 3, 4, and 5

PSA PFS is defined as the interval from study day 1 to the earlier of a PSA progression or death from any cause; otherwise, PSA PFS is censored on the date of the last PSA measurement. If a subject has no baseline or no post-baseline PSA measurement and a vital status of alive or unknown, PSA PFS will be censored at study day 1.

Time frame:
Up to 3 years
Reported as:
Median · Months
Progression Free Survival (PSA)- Parts 1, 2, 3, 4, and 5
MonthsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
Progression Free Survival (PSA)- Parts 1, 2, 3, 4, and 52.79 (1.41 to NA)3.60 (2.53 to NA)2.79 (NA to NA)3.02 (1.45 to NA)3.14 (0.72 to NA)2.23 (1.87 to NA)3.25 (2.14 to NA)2.48 (1.84 to NA)2.23 (1.87 to NA)4.75 (2.99 to NA)3.98 (3.06 to NA)4.83 (3.02 to NA)3.02 (2.99 to NA)5.85 (4.99 to NA)2.10 (NA to NA)3.63 (2.14 to NA)3.70 (2.10 to NA)3.06 (1.22 to NA)3.29 (2.07 to NA)3.01 (2.10 to NA)3.58 (3.02 to 4.90)5.63 (2.07 to NA)1.87 (1.51 to NA)8.54 (2.63 to NA)3.55 (2.10 to NA)NA (0.10 to NA)2.56 (2.40 to NA)2.89 (2.10 to NA)3.98 (2.14 to 4.80)3.38 (2.10 to 7.03)
SecondaryOverall Survival- Parts 1, 2, 3, 4, and 5

Overall survival (OS) is defined as the time from the date of study Day 1 until death due to any cause.

Time frame:
Up to 3 years
Reported as:
Median · Months
Overall Survival- Parts 1, 2, 3, 4, and 5
MonthsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
Overall Survival- Parts 1, 2, 3, 4, and 518.96 (1.41 to NA)11.32 (2.53 to NA)NA (NA to NA)11.43 (1.45 to NA)26.51 (0.72 to NA)NA (3.19 to NA)7.79 (2.79 to NA)8.28 (5.49 to NA)5.62 (2.23 to NA)7.75 (5.42 to NA)17.35 (4.60 to NA)18.14 (17.81 to NA)27.66 (13.44 to NA)NA (4.99 to NA)8.08 (NA to NA)NA (10.64 to NA)11.30 (6.90 to NA)6.51 (4.47 to NA)8.15 (4.50 to NA)16.39 (5.32 to NA)11.70 (8.64 to 14.59)6.90 (4.63 to NA)9.36 (6.57 to NA)22.67 (7.23 to NA)15.74 (4.04 to NA)NA (0.10 to NA)NA (2.40 to NA)4.96 (2.89 to NA)23.09 (10.58 to NA)13.24 (7.03 to NA)
SecondaryPercentage of Participants With Circulating Tumor Cell Response (CTC0)- Parts 1, 2, 3, 4, and 5

CTC0 is defined as reduction of CTCs \> 0 to 0 at any post-baseline measurement. CTC0 response is applicable only for participants with baseline CTC \> 0.

Time frame:
Up to 3 years
Reported as:
Number · Percentage of Participants
Percentage of Participants With Circulating Tumor Cell Response (CTC0)- Parts 1, 2, 3, 4, and 5
Percentage of ParticipantsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
Percentage of Participants With Circulating Tumor Cell Response (CTC0)- Parts 1, 2, 3, 4, and 50 (0.00 to 84.19)0 (0.00 to 84.19)—0 (0.00 to 84.19)100 (15.81 to 100.00)50 (1.26 to 98.74)66.7 (9.43 to 99.16)75 (19.41 to 99.37)33.3 (0.84 to 90.57)0 (0.00 to 60.24)20 (0.51 to 71.64)0 (0.00 to 84.19)100 (2.50 to 100.00)——0 (0.00 to 97.50)66.7 (9.43 to 99.16)0 (0.00 to 70.76)—0 (0.00 to 60.24)5.3 (0.13 to 26.03)20 (0.51 to 71.64)100 (2.50 to 100)100 (2.50 to 100)66.7 (9.43 to 99.16)0 (0.00 to 70.76)33.3 (0.84 to 90.57)0 (0.00 to 70.76)0 (0.00 to 21.80)0 (0.00 to 16.84)
SecondaryPercentage of Participants With CTC Conversion- Parts 1, 2, 3, 4, and 5

CTC conversion is defined as ≥ 5 CTCs/7.5 mL blood to ≤ 4 CTCs/7.5 mL blood at any post-baseline measurement. CTC conversion is applicable only for subjects with baseline CTC ≥ 5..

Time frame:
Up to 3 years
Reported as:
Number · Percentage of Participants
Percentage of Participants With CTC Conversion- Parts 1, 2, 3, 4, and 5
Percentage of ParticipantsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
Percentage of Participants With CTC Conversion- Parts 1, 2, 3, 4, and 50 (0.00 to 84.19)0 (0.00 to 84.19)—0 (0.00 to 84.19)100 (2.50 to 100.00)0 (0.00 to 97.50)100 (2.50 to 100.00)0 (0.00 to 97.50)33.3 (0.84 to 90.57)0 (0.00 to 84.19)0 (0.00 to 84.19)100 (2.50 to 100.00)100 (2.50 to 100.00)——0 (0.00 to 97.50)100 (29.24 to 100.00)33.3 (0.84 to 90.57)—33.3 (0.84 to 90.57)7.7 (0.19 to 36.03)20 (0.51 to 71.64)—100 (2.50 to 100)—100 (2.50 to 100.00)33.3 (0.84 to 90.57)33.3 (0.84 to 90.57)22.2 (2.81 to 60.01)38.5 (13.86 to 68.42)
SecondaryTime to Symptomatic Skeletal Events (SSE)- Parts 1, 2, 3, 4, and 5

Time to SSE is defined as time from study day 1 to the first SSE. Otherwise, SSE is censored at the last dose date of AMG 160 or pembrolizumab or end of safety follow up date, whichever is later.

Time frame:
Up to 3 years
Reported as:
Median · Months
Time to Symptomatic Skeletal Events (SSE)- Parts 1, 2, 3, 4, and 5
MonthsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
Time to Symptomatic Skeletal Events (SSE)- Parts 1, 2, 3, 4, and 5NA (NA to NA)NA (0.56 to NA)NA (NA to NA)NA (NA to NA)NA (1.87 to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)4.90 (NA to NA)NA (1.15 to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (17.58 to NA)NA (NA to NA)
SecondaryMaximum Observed Concentration (Cmax) of AMG 160 - Parts 1, 2, and 3

Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of pharmacokinetic (PK) parameters. Concentrations below the lower limit of quantification (LLOQ) (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

Time frame:
Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
Reported as:
Median · ng/mL
Maximum Observed Concentration (Cmax) of AMG 160 - Parts 1, 2, and 3
ng/mLPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf
Cycle 1 day 11.07 (0.561 to 1.41)5.26 (2.07 to 6.70)10.4 (10.4 to 10.4)2.95 (2.88 to 10.5)3.20 (1.67 to 4.64)2.07 (1.63 to 16.3)6.17 (5.21 to 10.1)7.09 (5.75 to 9.56)5.96 (3.40 to 14.9)8.56 (5.96 to 17.0)4.71 (3.27 to 6.15)8.40 (7.14 to 9.66)7.41 (5.64 to 9.17)11.6 (10.7 to 12.5)26.0 (26.0 to 26.0)10.7 (10.3 to 15.4)12.1 (9.57 to 14.2)10.3 (5.02 to 14.8)13.4 (9.39 to 20.3)15.4 (9.12 to 31.7)11.1 (3.73 to 75.0)3.68 (2.04 to 4.50)2.01 (1.85 to 2.13)12.4 (8.14 to 19.7)11.8 (7.76 to 14.8)12.5 (10.6 to 14.4)13.2 (5.76 to 15.5)16.2 (8.12 to 25.3)
Cycle 1 day 8———7.82 (6.98 to 9.78)17.7 (13.4 to 24.4)22.6 (18.9 to 41.1)21.0 (17.7 to 26.2)19.6 (13.8 to 25.2)21.0 (12.0 to 34.7)10.5 (10.1 to 12.7)24.4 (17.7 to 26.4)53.1 (53.1 to 53.1)64.8 (64.4 to 65.1)187 (150 to 223)172 (172 to 172)93.5 (88.8 to 99.6)66.9 (63.1 to 98.3)73.1 (43.9 to 92.4)25.1 (20.2 to 25.3)88.4 (71.5 to 119)66.6 (30.7 to 566)7.18 (5.14 to 11.0)16.0 (14.2 to 17.9)31.3 (27.1 to 43.1)65.0 (57.3 to 86.7)—16.2 (15.9 to 16.4)62.3 (54.8 to 86.8)
Cycle 1 day 150.812 (0.406 to 1.56)3.56 (1.85 to 6.30)———67.8 (0.932 to 91.2)191 (166 to 262)191 (141 to 194)209 (164 to 249)21.7 (18.0 to 25.2)————————————————153 (123 to 183)—
Cycle 1 day 22———6.90 (6.06 to 7.60)19.9 (16.7 to 23.0)————161 (50.9 to 236)16.6 (3.22 to 22.1)47.1 (41.2 to 53.0)——200 (200 to 200)113 (109 to 123)61.6 (13.1 to 85.2)67.7 (64.3 to 112)24.1 (3.02 to 40.6)92.3 (57.0 to 116)64.8 (10.8 to 492)7.50 (4.42 to 28.2)60.9 (53.4 to 61.2)21.3 (16.4 to 50.9)73.4 (73.4 to 73.4)——70.6 (65.7 to 73.5)
Cycle 2 day 11.96 (0.925 to 3.00)2.97 (2.21 to 5.72)—19.2 (6.86 to 31.5)19.1 (15.5 to 20.4)64.7 (4.20 to 77.7)188 (188 to 188)—251 (251 to 251)155 (49.0 to 214)17.5 (0.297 to 27.2)47.3 (45.0 to 51.6)59.6 (58.9 to 60.2)——95.4 (90.8 to 100)81.7 (68.1 to 82.6)63.3 (55.4 to 69.3)24.5 (0.621 to 49.0)72.2 (33.8 to 92.3)64.1 (3.80 to 109)5.99 (4.63 to 14.7)58.5 (56.6 to 61.9)31.7 (23.2 to 42.8)65.3 (64.3 to 66.3)46.7 (46.7 to 46.7)162 (140 to 184)59.0 (48.2 to 73.5)
Cycle 2 day 151.74 (1.12 to 2.35)3.67 (2.39 to 11.7)—7.71 (6.38 to 9.04)17.3 (7.13 to 18.9)47.0 (7.55 to 64.4)155 (155 to 155)178 (9.25 to 207)—171 (171 to 196)20.6 (16.6 to 23.8)48.6 (37.5 to 50.1)51.3 (46.6 to 56.0)——104 (104 to 104)48.7 (48.7 to 48.7)62.6 (0.00 to 89.1)23.0 (0.255 to 23.7)68.0 (60.7 to 99.7)60.9 (1.72 to 111)6.24 (4.31 to 9.42)51.4 (42.2 to 60.6)31.6 (27.0 to 50.1)—43.4 (43.4 to 43.4)142 (142 to 142)61.1 (51.7 to 70.5)
SecondaryTime to Cmax (Tmax) of AMG 160- Parts 1, 2, and 3

Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. Actual time post dose was used for calculations. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

Time frame:
Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 696 hours)
Reported as:
Median · hours
Time to Cmax (Tmax) of AMG 160- Parts 1, 2, and 3
hoursPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf
Cycle 1 day 11.8 (1.4 to 1.9)1.6 (1.1 to 1.7)1.9 (1.9 to 1.9)1.6 (1.1 to 2.1)1.8 (1.1 to 3.4)1.5 (1.2 to 3.6)1.7 (1.1 to 2.1)1.8 (1.6 to 4.5)1.4 (1.3 to 7.6)1.7 (1.5 to 170)61 (49 to 72)60 (48 to 72)72 (72 to 72)49 (48 to 49)73 (73 to 73)61 (48 to 74)72 (72 to 73)84 (48 to 170)72 (24 to 72)72 (24 to 72)72 (2.0 to 170)1.6 (1.3 to 1.7)1.7 (1.2 to 1.9)72 (48 to 72)72 (48 to 74)72 (72 to 72)7.5 (1.5 to 7.7)73 (69 to 170)
Cycle 1 day 8———1.6 (1.6 to 3.0)2.7 (1.6 to 3.8)1.6 (1.2 to 1.8)1.5 (1.3 to 1.8)1.6 (1.4 to 1.7)1.3 (1.0 to 1.6)1.6 (0.0 to 1.9)1.5 (1.1 to 1.8)1.6 (1.2 to 1.9)1.7 (1.7 to 1.7)1.9 (1.8 to 2.1)7.1 (7.1 to 7.1)1.6 (1.1 to 1.9)1.2 (1.1 to 1.9)1.6 (1.0 to 7.4)1.7 (1.6 to 1.8)1.6 (1.5 to 1.7)1.5 (0.67 to 73)1.6 (1.5 to 2.2)1.6 (1.2 to 1.9)1.6 (1.6 to 1.7)1.6 (1.1 to 6.1)—1.3 (1.1 to 1.6)1.5 (1.2 to 1.6)
Cycle 1 day 151.9 (1.0 to 3.1)1.6 (1.4 to 3.6)———1.6 (1.3 to 1.7)1.5 (1.1 to 1.8)1.6 (1.5 to 1.8)2.1 (1.6 to 2.6)1.6 (1.5 to 1.8)————————————1.6 (1.4 to 3.7)———1.6 (1.5 to 1.6)—
Cycle 1 day 22———1.6 (1.6 to 3.0)1.5 (1.3 to 1.7)————1.7 (1.6 to 2.0)1.8 (1.1 to 7.1)1.5 (1.3 to 1.7)——1.6 (1.6 to 1.6)1.2 (1.2 to 1.8)1.8 (1.6 to 48)1.5 (1.0 to 1.8)1.8 (1.7 to 1.9)1.8 (1.6 to 2.0)1.6 (0.92 to 26)1.6 (1.0 to 2.9)—1.6 (1.6 to 7.2)1.7 (1.7 to 1.7)——1.6 (1.4 to 6.6)
Cycle 2 day 11.6 (1.5 to 1.6)1.5 (1.3 to 1.7)—1.5 (1.3 to 1.7)1.5 (1.4 to 3.1)1.6 (1.2 to 1.7)1.8 (1.8 to 1.8)—1.6 (1.6 to 1.6)1.7 (1.5 to 1.8)1.6 (1.3 to 1.7)1.5 (1.3 to 3.6)2.1 (1.6 to 2.6)——1.3 (1.3 to 1.3)1.5 (1.2 to 1.6)1.6 (1.5 to 3.7)1.9 (1.8 to 1.9)1.9 (1.8 to 3.5)1.6 (0.0 to 24)1.7 (1.5 to 340)1.7 (1.3 to 1.9)4.1 (1.5 to 8.0)1.5 (1.4 to 1.7)1.7 (1.7 to 1.7)1.6 (1.5 to 1.6)2.4 (1.5 to 3.3)
Cycle 2 day 152.0 (1.3 to 2.7)1.7 (1.5 to 3.7)—2.4 (1.7 to 3.0)1.4 (1.1 to 1.7)1.6 (1.5 to 3.0)1.6 (1.6 to 1.6)1.7 (1.5 to 1.8)—1.6 (1.6 to 2.0)1.5 (0.97 to 1.7)1.6 (1.2 to 1.7)1.7 (1.6 to 1.8)——1.1 (1.1 to 1.1)1.2 (1.2 to 1.2)1.3 (0.0 to 2.8)1.8 (1.7 to 1.9)1.8 (1.5 to 3.7)1.6 (0.0 to 220)1.5 (1.5 to 2.1)1.6 (1.5 to 1.6)1.5 (1.4 to 6.8)—1.6 (1.6 to 1.6)3.5 (3.5 to 3.5)2.1 (1.6 to 2.7)
SecondaryMinimum Serum Concentration (Cmin) of AMG 160- Parts 1, 2, and 3

Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

Time frame:
Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))
Reported as:
Median · ng/mL
Minimum Serum Concentration (Cmin) of AMG 160- Parts 1, 2, and 3
ng/mLPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf
Cycle 1 day 10.0629 (0.00 to 0.0946)0.268 (0.0657 to 0.430)0.537 (0.537 to 0.537)0.452 (0.370 to 1.55)0.552 (0.00 to 0.784)0.631 (0.179 to 1.01)0.851 (0.168 to 1.55)0.900 (0.803 to 1.09)0.629 (0.367 to 2.48)6.67 (2.63 to 10.7)2.01 (1.24 to 2.78)2.90 (2.90 to 2.90)2.52 (2.41 to 2.62)4.18 (4.18 to 4.18)11.0 (11.0 to 11.0)4.13 (1.38 to 4.86)3.28 (2.40 to 4.46)9.87 (4.94 to 14.8)4.31 (3.76 to 4.58)4.89 (3.32 to 8.48)4.11 (0.712 to 47.8)0.311 (0.0765 to 0.462)0.331 (0.326 to 0.339)4.73 (4.63 to 4.84)3.82 (3.25 to 5.48)4.54 (3.44 to 5.64)1.70 (1.56 to 1.84)7.87 (5.42 to 8.12)
Cycle 1 day 8———0.617 (0.450 to 0.881)1.19 (0.790 to 1.98)—2.66 (1.12 to 3.01)2.17 (1.52 to 3.55)1.92 (1.04 to 3.40)—1.99 (0.435 to 2.38)3.88 (3.88 to 3.88)3.79 (3.79 to 3.79)8.76 (8.76 to 8.76)10.4 (10.4 to 10.4)3.74 (3.60 to 6.79)4.09 (1.91 to 5.61)5.50 (0.00 to 13.4)1.58 (0.181 to 2.22)3.46 (2.44 to 7.13)4.94 (0.179 to 15.4)0.369 (0.252 to 0.807)2.79 (2.24 to 3.04)3.68 (1.68 to 3.70)4.41 (4.41 to 4.41)—2.76 (2.31 to 3.20)3.45 (2.87 to 8.47)
Cycle 1 day 150.100 (0.0730 to 0.127)0.245 (0.0923 to 0.551)———2.44 (0.00 to 4.17)3.48 (0.00 to 6.80)8.16 (0.794 to 10.2)4.56 (4.32 to 6.18)2.79 (0.00 to 4.67)————————————3.16 (2.01 to 4.13)———6.44 (5.63 to 7.24)—
Cycle 1 day 22———0.616 (0.443 to 0.789)1.24 (0.972 to 1.49)————6.24 (0.00 to 14.4)2.04 (0.00 to 2.25)2.19 (0.474 to 3.90)——11.5 (11.5 to 11.5)4.63 (3.71 to 5.55)2.34 (1.71 to 2.60)5.44 (2.92 to 7.96)1.76 (0.00 to 2.72)3.64 (2.83 to 4.25)4.62 (0.00 to 14.6)0.440 (0.298 to 1.07)—1.84 (1.73 to 3.79)———3.60 (3.35 to 3.84)
Cycle 2 day 10.164 (0.0916 to 0.236)0.235 (0.120 to 0.491)—1.29 (0.483 to 2.10)1.25 (0.113 to 1.59)0.650 (0.00 to 1.30)5.31 (5.31 to 5.31)——8.57 (4.43 to 11.5)1.81 (0.979 to 1.89)3.20 (0.533 to 3.67)2.55 (2.44 to 2.65)——5.37 (4.92 to 5.82)2.72 (2.20 to 3.23)5.40 (2.78 to 8.02)1.73 (0.00 to 4.15)3.33 (1.79 to 3.78)4.36 (0.00 to 81.3)0.278 (0.00 to 14.7)2.95 (1.75 to 4.14)2.29 (2.12 to 3.75)0.00 (0.00 to 0.00)3.18 (3.18 to 3.18)7.27 (7.27 to 7.27)3.48 (2.99 to 3.96)
Cycle 2 day 150.153 (0.115 to 0.191)0.250 (0.176 to 0.827)—0.700 (0.439 to 0.960)1.21 (0.00 to 1.90)0.853 (0.00 to 2.31)7.51 (7.51 to 7.51)4.27 (0.00 to 6.87)—7.19 (4.18 to 10.2)1.49 (0.796 to 2.27)4.66 (3.94 to 5.37)2.58 (2.16 to 3.00)——6.40 (5.23 to 7.57)1.69 (1.69 to 1.69)3.65 (3.43 to 7.64)1.96 (1.41 to 2.50)4.15 (3.40 to 5.89)4.18 (0.00 to 21.6)0.300 (0.285 to 0.315)0.423 (0.423 to 0.423)2.90 (1.44 to 3.86)—3.05 (3.05 to 3.05)6.83 (6.83 to 6.83)3.02 (3.02 to 3.02)
SecondaryArea Under the Concentration-time Curve (AUC) From Time 0 to Last Quantifiable Concentration (AUClast) of AMG 160- Parts 1, 2, and 3

Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

Time frame:
Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))
Reported as:
Median · hour*ng/mL
Area Under the Concentration-time Curve (AUC) From Time 0 to Last Quantifiable Concentration (AUClast) of AMG 160- Parts 1, 2, and 3
hour*ng/mLPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf
Cycle 1 day 184.4 (33.1 to 114)379 (126 to 485)759 (759 to 759)170 (166 to 625)200 (68.3 to 308)145 (77.9 to 1190)380 (308 to 614)422 (367 to 457)282 (177 to 940)505 (186 to 905)581 (332 to 831)586 (456 to 717)825 (607 to 1040)813 (498 to 1130)2760 (2760 to 2760)1160 (1040 to 2570)1290 (957 to 2840)1010 (131 to 1760)1050 (752 to 1970)1670 (1150 to 3170)1140 (197 to 5890)123 (70.1 to 211)123 (116 to 144)1090 (651 to 1330)998 (524 to 1330)1360 (1300 to 1430)727 (164 to 914)1650 (959 to 2750)
Cycle 1 day 8———734 (551 to 822)1260 (308 to 1610)828 (724 to 1020)1070 (720 to 1090)924 (644 to 1190)832 (531 to 1720)423 (357 to 794)2010 (1100 to 2430)3640 (3130 to 4150)3570 (2970 to 4160)11400 (11300 to 11600)13500 (13500 to 13500)6010 (4630 to 6820)5030 (3260 to 6340)5200 (529 to 7340)2020 (1520 to 2020)4940 (3680 to 7400)5660 (1720 to 8710)599 (131 to 1170)856 (821 to 912)2710 (2060 to 3560)4020 (3820 to 5230)—1030 (1020 to 1050)5050 (4300 to 8190)
Cycle 1 day 1578.0 (12.9 to 132)322 (131 to 658)———4370 (25.1 to 6690)10400 (4150 to 13600)11600 (8850 to 16900)12200 (7630 to 14200)1060 (495 to 1620)————————————4370 (3960 to 4710)———12000 (10900 to 13200)—
Cycle 1 day 22———497 (492 to 678)1610 (1090 to 1860)————9100 (310 to 16300)1840 (17.0 to 2090)3080 (1890 to 4270)——11200 (11200 to 11200)6430 (4160 to 7620)4310 (1840 to 4350)4330 (1830 to 9340)1960 (42.0 to 3400)5720 (4430 to 5980)5420 (84.4 to 11200)806 (408 to 1150)—2080 (1870 to 4350)4360 (4360 to 4360)——4800 (4650 to 5870)
Cycle 2 day 1138 (92.3 to 243)280 (167 to 507)—1440 (537 to 2340)1320 (645 to 1820)2330 (53.3 to 5710)9780 (9780 to 9780)—11300 (11300 to 11300)9240 (451 to 14500)1600 (0.605 to 2290)3030 (1960 to 4730)3420 (3370 to 3470)——6000 (5640 to 6350)3670 (2850 to 4350)3980 (353 to 6600)2020 (1.33 to 4010)4710 (2710 to 5570)5220 (18.1 to 12600)420 (129 to 2000)3190 (1970 to 4400)2870 (2100 to 3720)2440 (1260 to 3610)3570 (3570 to 3570)6570 (4540 to 8600)5040 (4310 to 5770)
Cycle 2 day 15178 (126 to 230)306 (138 to 1030)—710 (547 to 873)1330 (121 to 1850)3030 (78.3 to 3250)9470 (9470 to 9470)9430 (22.9 to 12200)—9090 (7820 to 11100)1660 (1100 to 2220)4290 (1510 to 4810)3260 (2870 to 3640)——7350 (6930 to 7770)3430 (3430 to 3430)5580 (5100 to 7550)1770 (0.223 to 2080)5550 (3940 to 6510)5190 (7.60 to 12400)372 (107 to 536)2930 (2670 to 3190)2560 (2050 to 3990)—3490 (3490 to 3490)8640 (8640 to 8640)4090 (404 to 4130)
SecondaryAUC Over the Dosing Interval (AUCtau)- Parts 1, 2, and 3

Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

Time frame:
Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
Reported as:
Median · hour*ng/mL
AUC Over the Dosing Interval (AUCtau)- Parts 1, 2, and 3
hour*ng/mLPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf
Cycle 1 day 184.6 (39.5 to 114)379 (126 to 486)761 (761 to 761)171 (167 to 627)200 (71.4 to 308)145 (79.0 to 901)340 (309 to 620)425 (348 to 458)285 (177 to 999)303 (298 to 865)765 (765 to 765)716 (716 to 716)786 (604 to 967)1130 (1130 to 1130)2750 (2750 to 2750)1690 (1690 to 1690)1340 (1230 to 1860)1510 (1260 to 1750)1500 (1050 to 1960)1510 (1060 to 3160)1120 (487 to 5440)164 (70.1 to 212)124 (116 to 136)1240 (921 to 1330)1090 (914 to 1260)1230 (1230 to 1230)821 (728 to 913)945 (945 to 945)
Cycle 1 day 8———735 (554 to 809)1320 (356 to 1800)1160 (964 to 1260)1080 (692 to 1100)929 (648 to 1270)847 (532 to 1730)582 (422 to 802)2010 (1100 to 2430)4030 (3920 to 4150)3890 (3510 to 4260)12700 (11600 to 13900)13500 (13500 to 13500)6140 (5220 to 6790)5000 (3820 to 6240)5480 (4040 to 7350)2020 (1440 to 2030)5420 (3680 to 7400)5750 (2700 to 8770)496 (170 to 807)924 (833 to 927)2790 (2060 to 3560)5280 (4820 to 5340)—1030 (1020 to 1050)5050 (4300 to 8190)
Cycle 1 day 1578.1 (26.5 to 133)319 (132 to 660)———4330 (29.8 to 6700)9930 (4160 to 12200)11700 (10100 to 16900)10900 (7630 to 14200)1100 (503 to 1620)————————————4110 (3970 to 4370)———12000 (10900 to 13200)—
Cycle 1 day 22———484 (384 to 488)1230 (822 to 1460)————7440 (310 to 12000)1270 (49.7 to 1580)2430 (1670 to 3200)——8930 (8930 to 8930)4840 (4140 to 6340)3380 (1320 to 3750)3470 (2900 to 6250)1590 (46.5 to 2540)4460 (3440 to 5960)4320 (97.3 to 7390)595 (286 to 965)—1660 (1290 to 3210)4390 (4390 to 4390)——3980 (3890 to 5860)
Cycle 2 day 1168 (92.6 to 243)282 (168 to 508)—1440 (539 to 2340)1320 (645 to 1820)3010 (58.4 to 5190)9660 (9660 to 9660)—12100 (12100 to 12100)9240 (475 to 14500)1870 (920 to 2290)3040 (1960 to 4650)3410 (3360 to 3470)——6010 (5660 to 6370)3670 (3250 to 4350)5380 (3980 to 6780)3070 (2020 to 4110)4700 (2710 to 5490)5260 (19.1 to 12600)420 (247 to 1990)3200 (3090 to 4420)2790 (2140 to 3730)3640 (3040 to 4240)3650 (3650 to 3650)8030 (7460 to 8600)5040 (4320 to 5770)
Cycle 2 day 15178 (126 to 230)304 (170 to 1030)—710 (548 to 872)1320 (124 to 1890)3030 (88.4 to 3260)9660 (9660 to 9660)9580 (35.6 to 11100)—11100 (7820 to 11100)1640 (1380 to 2310)4360 (1640 to 4920)3290 (2870 to 3720)——7280 (6790 to 7770)3430 (3430 to 3430)5580 (5020 to 7530)1950 (1770 to 2130)5380 (4590 to 6510)5250 (8.53 to 12000)372 (123 to 536)3220 (2640 to 3790)2540 (2450 to 3990)—3490 (3490 to 3490)8800 (8800 to 8800)4430 (4130 to 4730)
SecondaryTerminal Half-life (t1/2,z) of AMG 160- Parts 1, 2, and 3

Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

Time frame:
Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
Reported as:
Median · hours
Terminal Half-life (t1/2,z) of AMG 160- Parts 1, 2, and 3
hoursPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf
Cycle 1 day 198.1 (68.3 to 121)98.7 (88.9 to 128)108 (108 to 108)74.7 (74.7 to 74.7)21.5 (21.5 to 21.5)85.2 (65.1 to 105)66.1 (59.3 to 72.9)61.7 (52.2 to 71.1)68.5 (59.6 to 77.5)————————————71.4 (47.1 to 76.3)————62.3 (62.3 to 62.3)—
Cycle 1 day 8———120 (117 to 123)124 (27.9 to 129)27.3 (27.3 to 27.3)76.1 (74.7 to 77.6)52.5 (52.5 to 52.5)72.1 (69.8 to 74.4)29.3 (29.3 to 29.3)113 (71.8 to 127)137 (137 to 137)102 (81.2 to 123)115 (115 to 115)124 (124 to 124)114 (106 to 130)96.3 (70.6 to 132)109 (105 to 114)95.3 (50.9 to 140)88.0 (83.0 to 113)105 (40.1 to 146)109 (92.6 to 136)—115 (106 to 123)118 (118 to 118)—75.9 (75.9 to 75.9)91.3 (90.8 to 124)
Cycle 1 day 15131 (129 to 133)113 (108 to 128)———96.4 (22.9 to 111)113 (14.3 to 136)74.2 (44.8 to 129)98.5 (79.5 to 152)11.3 (11.3 to 11.3)————————————138 (118 to 152)———93.6 (93.6 to 93.6)—
Cycle 1 day 22———127 (127 to 127)112 (86.8 to 126)————104 (80.6 to 126)127 (120 to 150)105 (70.7 to 139)——94.5 (94.5 to 94.5)94.8 (48.3 to 132)89.7 (68.6 to 96.3)117 (93.6 to 141)99.0 (13.3 to 106)96.3 (68.0 to 112)112 (68.0 to 142)103 (84.8 to 159)—135 (134 to 136)71.6 (71.6 to 71.6)——83.1 (68.2 to 91.5)
Cycle 2 day 1131 (127 to 136)113 (106 to 118)—127 (125 to 130)108 (62.5 to 142)70.2 (22.1 to 115)117 (117 to 117)—69.3 (69.3 to 69.3)100 (59.3 to 126)116 (104 to 116)119 (72.9 to 157)118 (101 to 134)——131 (122 to 139)74.5 (62.3 to 97.5)109 (95.8 to 122)115 (106 to 123)109 (82.5 to 144)102 (5.20 to 146)104 (47.8 to 111)102 (86.0 to 117)106 (95.2 to 133)70.0 (70.0 to 70.0)108 (108 to 108)107 (107 to 107)99.1 (93.9 to 104)
Cycle 2 day 15111 (110 to 113)105 (101 to 117)—125 (108 to 141)114 (40.1 to 129)68.1 (9.53 to 123)113 (113 to 113)118 (102 to 134)—129 (114 to 144)108 (92.1 to 111)110 (55.7 to 120)105 (97.6 to 113)——125 (116 to 134)85.6 (85.6 to 85.6)100 (98.4 to 104)124 (111 to 138)101 (68.6 to 148)101 (5.73 to 135)98.1 (24.4 to 120)66.8 (66.8 to 66.8)109 (72.3 to 135)—104 (104 to 104)90.8 (90.8 to 90.8)87.9 (69.8 to 106)
PrimaryNumber of Participants With Treatment Emergent Adverse Events- Parts 1, 2, 3, 4, and 5

A treatment-emergent adverse event is one that occurs on or after the first dose of study treatment and up to 30 days after the last dose. Adverse events were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any clinically significant changes in vital signs, electrocardiograms, and clinical laboratory tests were recorded as adverse events.

Time frame:
Up to 30 days after the last dose of study drug, or start of new anti-cancer therapy, whichever occurs first
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events- Parts 1, 2, 3, 4, and 5
ParticipantsPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
Treatment-emergent Adverse Events241364443464321446475663573332623
Treatment (AMG 160) Related Treatment-emergent Adverse Events241364443464321446475663573332623
Treatment (Pembrolizumab) Related Treatment-emergent Adverse Events—————————————————————53441————
Treatment (Etanercept) Related Treatment-emergent Adverse Events——————————————————————————01——

Adverse events

Collected over Death: From enrollment through end of study; median (min, max) time on study was 10.5 (0.1, 37.9) months. TEAE: From 1st dose of investigational product (IP) (AMG 160 or Pembrolizumab) date to min(last dose of IP date + 30 days, EOS date , start of new anti-cancer therapy date); median (min, max) duration was 3 (0, 23.5) months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1A: AMG 160 Monotherapy 0.003 mg3/3 (100%)1/3 (33.3%)2/3 (66.7%)
Part 1A: AMG 160 Monotherapy 0.01 mg4/4 (100%)3/4 (75%)4/4 (100%)
Part 1A: AMG 160 Monotherapy 0.03 mg0/1 (0%)1/1 (100%)1/1 (100%)
Part 1A: AMG 160 Monotherapy 0.03 mg SD13/3 (100%)3/3 (100%)3/3 (100%)
Part 1A: AMG 160 Monotherapy 0.09 mg SD24/6 (66.7%)5/6 (83.3%)6/6 (100%)
Part 1A: AMG 160 Monotherapy 0.3 mg SD32/4 (50%)4/4 (100%)4/4 (100%)
Part 1A: AMG 160 Monotherapy 0.9 mg SD44/4 (100%)2/4 (50%)4/4 (100%)
Part 1A: AMG 160 Monotherapy 0.9 mg SD53/4 (75%)4/4 (100%)4/4 (100%)
Part 1A: AMG 160 0.9 mg + Tocilizumab SD63/3 (100%)3/3 (100%)3/3 (100%)
Part 1A: AMG 160 Monotherapy 0.9 mg SD74/4 (100%)4/4 (100%)4/4 (100%)
Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-Inf3/6 (50%)2/6 (33.3%)6/6 (100%)
Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-Inf3/4 (75%)2/4 (50%)4/4 (100%)
Part 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-Inf2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-Inf1/2 (50%)0/2 (0%)2/2 (100%)
Part 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-Inf1/1 (100%)0/1 (0%)1/1 (100%)
Part 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-Inf2/4 (50%)2/4 (50%)4/4 (100%)
Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-Inf3/4 (75%)3/4 (75%)4/4 (100%)
Part 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-Inf4/6 (66.7%)4/6 (66.7%)6/6 (100%)
Part 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-Inf4/4 (100%)1/4 (25%)4/4 (100%)
Part 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-Inf5/7 (71.4%)0/7 (0%)7/7 (100%)
Part 1: AMG Monotherapy DE (Dose F)40/56 (71.4%)29/56 (51.8%)56/56 (100%)
Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC16/6 (100%)3/6 (50%)6/6 (100%)
Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC23/3 (100%)2/3 (66.7%)3/3 (100%)
Part 2: AMG 160 + Pembrolizumab Dose E eIVPC3-3d-Inf3/5 (60%)2/5 (40%)5/5 (100%)
Part 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-Inf4/7 (57.1%)6/7 (85.7%)7/7 (100%)
Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2D1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Part 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC11/3 (33.3%)1/3 (33.3%)3/3 (100%)
Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-Inf2/3 (66.7%)0/3 (0%)3/3 (100%)
Part 4: AMG 160 Monotherapy 0.3 mg 24HR11/26 (42.3%)12/26 (46.2%)26/26 (100%)
Part 5: AMG 160 Monotherapy 0.3 mg 8HR11/23 (47.8%)15/23 (65.2%)23/23 (100%)
Most frequent serious events
Showing 10 of 95
Most frequent serious events
EventPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab Dose E eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
Cytokine release syndromeImmune system disorders0/32/41/10/32/63/40/43/41/33/41/61/40/30/20/10/40/40/61/40/718/560/60/30/53/70/30/30/310/2612/23
ArthralgiaMusculoskeletal and connective tissue disorders0/30/41/10/30/60/40/40/40/30/40/60/40/30/20/10/40/40/60/40/70/560/60/30/50/70/30/30/30/260/23
Groin painMusculoskeletal and connective tissue disorders0/30/41/10/30/60/40/40/40/30/40/60/40/30/20/10/40/40/60/40/70/560/60/30/50/70/30/30/30/260/23
RashSkin and subcutaneous tissue disorders0/30/41/10/30/60/40/40/40/30/40/60/40/30/20/10/40/40/60/40/70/560/60/30/50/70/30/30/30/260/23
Back painMusculoskeletal and connective tissue disorders0/30/40/12/30/60/40/40/40/30/40/60/40/30/20/10/40/40/60/40/71/560/60/30/50/70/30/30/30/260/23
AnaemiaBlood and lymphatic system disorders0/30/40/11/30/60/40/40/40/30/40/60/40/30/20/10/40/41/60/40/72/560/60/30/50/70/30/30/30/261/23
ThrombocytopeniaBlood and lymphatic system disorders0/30/40/10/30/60/40/40/40/30/40/60/40/30/20/10/40/40/60/40/70/560/60/30/50/70/31/30/30/260/23
Atrial fibrillationCardiac disorders0/30/40/10/31/61/41/40/40/31/40/60/40/30/20/10/41/40/60/40/71/562/60/30/50/70/31/30/30/260/23
Cardiac arrestCardiac disorders0/30/40/10/30/60/40/40/40/30/40/60/40/30/20/10/40/40/60/40/70/560/60/30/50/71/30/30/30/260/23
HypoacusisEar and labyrinth disorders0/30/40/10/30/60/40/40/41/30/40/60/40/30/20/10/40/40/60/40/70/560/60/30/50/70/30/30/30/260/23
Most frequent other events
Showing 10 of 352
Most frequent other events
EventPart 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy DE (Dose F)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab Dose E eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HR
LymphopeniaBlood and lymphatic system disorders0/30/41/10/30/60/40/42/40/31/40/61/40/30/20/10/40/40/60/40/72/560/60/30/50/70/30/30/30/260/23
HypoacusisEar and labyrinth disorders0/30/40/11/30/60/40/40/40/30/40/60/40/32/21/10/40/40/60/41/79/560/62/30/51/70/30/31/31/261/23
TinnitusEar and labyrinth disorders0/30/40/10/30/60/41/40/40/30/41/60/41/31/21/11/40/42/60/40/71/560/61/30/50/70/30/30/32/261/23
VertigoEar and labyrinth disorders0/30/40/11/30/60/40/40/40/30/40/60/40/30/21/10/40/40/60/40/70/560/61/31/50/70/30/30/31/260/23
Abdominal distensionGastrointestinal disorders1/30/41/10/30/60/40/40/40/30/40/60/40/30/20/10/40/40/60/40/71/560/60/30/50/71/30/30/31/260/23
DiarrhoeaGastrointestinal disorders0/31/40/12/33/61/42/40/41/32/46/62/43/31/21/12/42/43/61/40/730/565/62/32/52/73/33/31/314/266/23
Dry mouthGastrointestinal disorders0/30/40/11/33/62/43/40/40/33/42/62/41/31/21/12/42/44/60/41/723/560/62/31/52/70/30/32/38/264/23
NauseaGastrointestinal disorders0/31/41/11/34/61/42/42/41/32/44/62/42/32/20/10/41/41/61/42/732/566/62/33/52/72/33/33/319/2611/23
VomitingGastrointestinal disorders1/31/40/13/34/62/41/40/40/31/44/62/42/32/20/10/41/42/60/41/726/564/62/32/53/71/32/31/313/267/23
FatigueGeneral disorders0/32/41/13/33/63/43/42/42/32/46/62/42/32/20/13/41/43/60/40/732/564/63/31/52/72/31/32/311/2611/23

Baseline characteristics

Safety analysis set: all participants who were enrolled and received at least one dose of AMG 160 or pembrolizumab.

Age, Customized
Age, Customized(Participants)Part 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy Dose Expansion (DE) (0.3 mg)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HRTotal
18 - 64 years1013221322320113123321411211091490
65 - 74 years2400323012212100140227024522212894
75 - 84 years00001001001110012012720000014126
≥ 85 years0000000000000000000010000000102
Sex: Female, Male
Sex: Female, Male(Participants)Part 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy Dose Expansion (DE) (0.3 mg)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HRTotal
Female0000000000000000000000000000000
Male341364443464321446475663573332623212
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy Dose Expansion (DE) (0.3 mg)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HRTotal
Hispanic or Latino0001000000000000100020010000117
Not Hispanic or Latino341263443464321435475363473332522202
Unknown or Not Reported0000010000000000010010000000003
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1A: AMG 160 Monotherapy 0.003 mgPart 1A: AMG 160 Monotherapy 0.01 mgPart 1A: AMG 160 Monotherapy 0.03 mgPart 1A: AMG 160 Monotherapy 0.03 mg SD1Part 1A: AMG 160 Monotherapy 0.09 mg SD2Part 1A: AMG 160 Monotherapy 0.3 mg SD3Part 1A: AMG 160 Monotherapy 0.9 mg SD4Part 1A: AMG 160 Monotherapy 0.9 mg SD5Part 1A: AMG 160 0.9 mg + Tocilizumab SD6Part 1A: AMG 160 Monotherapy 0.9 mg SD7Part 1B1: AMG 160 Monotherapy 0.09 mg eIV1-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-2d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV2-3d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-2d-InfPart 1B1: AMG 160 Monotherapy 0.9 mg eIV3-3d-InfPart 1B1: AMG 160 Monotherapy 0.6 mg eIV4-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-3d-InfPart 1B1: AMG 160 Monotherapy 0.3 mg eIV5-5d-InfPart 1B2: AMG 160 Monotherapy 0.09 mg eIVJC1-3d-InfPart 1B2: AMG 160 Monotherapy 0.3 mg eIVJC2-3d-InfPart 1: AMG Monotherapy Dose Expansion (DE) (0.3 mg)Part 2: AMG 160 + Pembrolizumab 0.03 mg SDPC1Part 2: AMG 160 + Pembrolizumab 0.3 mg SDPC2Part 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-InfPart 2: AMG 160 + Pembrolizumab 0.3 mg eIVPC4-3d-InfPart 2: AMG 160 + Pembrolizumab 0.15 mg eIVPC3-3d-Inf D-RP2DPart 3: AMG 160 With CRS Prophylaxis 0.9 mg SDEC1Part 3: AMG 160 With CRS Prophylaxis 0.3 mg eIVEC1-3d-InfPart 4: AMG 160 Monotherapy 0.3 mg 24HRPart 5: AMG 160 Monotherapy 0.3 mg 8HRTotal
American Indian or Alaska Native0000000000000000000000000000000
Asian100000000100000002471000021000129
Native Hawaiian or Other Pacific Islander0000000000000000000000000000000
Black or African American00000100100010000100100000005515
White241361322354221442003363442332017146
More than one race0000000000000000000000000000000
Unknown or Not Reported000002120010000001001200110001022
08

Study locations

30 sites
  • El Camino Hospital
    Campbell, California 95008, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • City of Hope at Long Beach Elm
    Long Beach, California 90813, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Tulane Medical Center
    New Orleans, Louisiana 70112, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Chris OBrien Lifehouse
    Camperdown, New South Wales 2050, Australia
  • Scientia Clinical Research Ltd
    Randwick, New South Wales 2031, Australia
  • Peter MacCallum Cancer Centre
    Parkville, Victoria 3050, Australia
  • Ordensklinikum Linz Elisabethinen
    Linz, 4020, Austria
  • Landeskrankenhaus Salzburg
    Salzburg, 5020, Austria
  • Krankenhaus der Barmherzigen Brueder Wien
    Vienna, 1020, Austria
  • Universitaetsklinikum Allgemeines Krankenhaus Wien
    Vienna, 1090, Austria
  • Universite Catholique de Louvain Cliniques Universitaires Saint Luc
    Brussels, 1200, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • BC Cancer Vancouver
    Vancouver, British Columbia V5Z 4E6, Canada
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • National Cancer Center Hospital East
    Kashiwa-shi, Chiba 277-8577, Japan
  • Yokohama City University Medical Center
    Yokohama, Kanagawa 232-0024, Japan
  • Erasmus Medisch Centrum
    Rotterdam, 3015 GD, Netherlands
  • National University Hospital
    Singapore, 119074, Singapore
  • National Cancer Centre Singapore
    Singapore, 169610, Singapore
  • Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation
    Taoyuan, 33305, Taiwan
09

References and documents

Publications

  • Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, Greil R, Matsubara N, Tan DSW, Wong A, Uemura H, Lemech C, Meran J, Yu Y, Minocha M, McComb M, Penny HL, Gupta V, Hu X, Jurida G, Kouros-Mehr H, Janat-Amsbury MM, Eggert T, Tran B. A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Apr 15;30(8):1488-1500. doi: 10.1158/1078-0432.CCR-23-2978. PubMed 38300720 ↗
  • Hushmandi K, Einollahi B, Lee EHC, Sakaizawa R, Glaviano A, Reiter RJ, Saadat SH, Farani MR, Huh YS, Aref AR, Salimimoghadam S, Kumar AP. Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence. Int J Biol Sci. 2025 Jan 27;21(4):1410-1435. doi: 10.7150/ijbs.96155. eCollection 2025. PubMed 39990653 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Jun 2023, 52 months.

Results were first posted in Nov 2026, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2019
First posted
Jan 3, 2019
StartActual
Feb 5, 2019
Primary completionActual
Jun 29, 2023
CompletionActual
Jun 29, 2023
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 10, 2026
Primary outcomes
2 edited, 4 removed
What changed in the outcomes
  • EditedNumber of participants with doseParticipants With a Dose Limiting Toxicity (DLT)-limiting toxicity Parts 1 and 2Time frame: Up to 3 years → Day 1 to 28 of Cycle 1 (length of cycle is 28 days)
  • EditedNumber of participants with treatmentParticipants With Treatment Emergent Adverse Events-emergent adverse events Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years → Up to 30 days after the last dose of study drug, or start of new anti-cancer therapy, whichever occurs first
  • RemovedNumber of participants with treatment-related adverse eventsTime frame: Up to 3 years
  • RemovedNumber of participants with clinically significant changes in vital signsTime frame: Up to 3 years
  • RemovedNumber of participants with clinically significant changes in electrocardiogram (ECG)Time frame: Up to 3 years
  • RemovedNumber of participants with clinically significant changes in clinical laboratory testsTime frame: Up to 3 years
Nov 10, 2026
Documents
Secondary outcomes
3 edited, 17 added, 10 removed, 10 more
What changed in the outcomes
  • EditedMinimum serum concentrationSerum Concentration (Cmin) of acapatamabAMG 160- Parts 1, 2, and 3Time frame: Up to 3 years → Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))
  • EditedProstate-specific antigenAntigen (PSA) responseResponse- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
  • EditedPercentage of participants experiencing a response based onParticipants With 68Gallium (68Ga)-prostateProstate-specific membrane antigenMembrane Antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) response evaluations Response Parts 1, 2, and 3Time frame: Up to 3 years
  • AddedObjective Response (OR) Rate- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
  • AddedDuration of Response (DOR)-RECIST 1.1- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
  • AddedDuration of PSA Response- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
  • AddedPercentage of Participants With F-fluorodeoxyglucose (FDG) Response- Parts 1, 2, and 3Time frame: Up to 3 years
  • AddedTime to Progression (Radiographic)- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
  • AddedTime to Progression (PSA)- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
  • AddedProgression Free Survival (Radiographic)- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
  • AddedProgression Free Survival (PSA)- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
  • AddedOverall Survival- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
  • AddedPercentage of Participants With Circulating Tumor Cell Response (CTC0)- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
  • AddedPercentage of Participants With CTC Conversion- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
  • AddedTime to Symptomatic Skeletal Events (SSE)- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
  • AddedMaximum Observed Concentration (Cmax) of AMG 160 - Parts 1, 2, and 3Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
  • AddedTime to Cmax (Tmax) of AMG 160- Parts 1, 2, and 3Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 696 hours)
  • AddedArea Under the Concentration-time Curve (AUC) From Time 0 to Last Quantifiable Concentration (AUClast) of AMG 160- Parts 1, 2, and 3Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))
  • AddedAUC Over the Dosing Interval (AUCtau)- Parts 1, 2, and 3Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
  • AddedTerminal Half-life (t1/2,z) of AMG 160- Parts 1, 2, and 3Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
  • RemovedMaximum serum concentration (Cmax) of acapatamabTime frame: Up to 3 years
  • RemovedArea under the concentration-time curve (AUC) over the dosing interval of acapatamabTime frame: Up to 3 years
  • RemovedAccumulation ratio of acapatamabTime frame: Up to 3 years
  • RemovedHalf-life of acapatamabTime frame: Up to 3 years
  • RemovedObjective response (OR)Time frame: Up to 3 years
  • RemovedDuration of response (DOR) (radiographic and PSA)Time frame: Up to 3 years
  • RemovedPercentage of participants experiencing a response based on 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) response evaluationsTime frame: Up to 3 years
  • RemovedChange in time to progression (radiographic and PSA)Time frame: Up to 3 years
  • RemovedProgression-free survival (PFS) (radiographic and PSA)Time frame: Up to 3 years
  • Removed1, 2 and 3-year overall survival (OS)Time frame: Up to 3 years
  • …and 10 more, on the record history on ClinicalTrials.gov ↗
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Results posted
    Primary outcomes 2 edited, 4 removed
    What changed in the outcomes
    • EditedNumber of participants with doseParticipants With a Dose Limiting Toxicity (DLT)-limiting toxicity Parts 1 and 2Time frame: Up to 3 years → Day 1 to 28 of Cycle 1 (length of cycle is 28 days)
    • EditedNumber of participants with treatmentParticipants With Treatment Emergent Adverse Events-emergent adverse events Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years → Up to 30 days after the last dose of study drug, or start of new anti-cancer therapy, whichever occurs first
    • RemovedNumber of participants with treatment-related adverse eventsTime frame: Up to 3 years
    • RemovedNumber of participants with clinically significant changes in vital signsTime frame: Up to 3 years
    • RemovedNumber of participants with clinically significant changes in electrocardiogram (ECG)Time frame: Up to 3 years
    • RemovedNumber of participants with clinically significant changes in clinical laboratory testsTime frame: Up to 3 years
    Secondary outcomes 3 edited, 17 added, 10 removed, 10 more
    What changed in the outcomes
    • EditedMinimum serum concentrationSerum Concentration (Cmin) of acapatamabAMG 160- Parts 1, 2, and 3Time frame: Up to 3 years → Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))
    • EditedProstate-specific antigenAntigen (PSA) responseResponse- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
    • EditedPercentage of participants experiencing a response based onParticipants With 68Gallium (68Ga)-prostateProstate-specific membrane antigenMembrane Antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) response evaluations Response Parts 1, 2, and 3Time frame: Up to 3 years
    • AddedObjective Response (OR) Rate- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
    • AddedDuration of Response (DOR)-RECIST 1.1- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
    • AddedDuration of PSA Response- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
    • AddedPercentage of Participants With F-fluorodeoxyglucose (FDG) Response- Parts 1, 2, and 3Time frame: Up to 3 years
    • AddedTime to Progression (Radiographic)- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
    • AddedTime to Progression (PSA)- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
    • AddedProgression Free Survival (Radiographic)- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
    • AddedProgression Free Survival (PSA)- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
    • AddedOverall Survival- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
    • AddedPercentage of Participants With Circulating Tumor Cell Response (CTC0)- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
    • AddedPercentage of Participants With CTC Conversion- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
    • AddedTime to Symptomatic Skeletal Events (SSE)- Parts 1, 2, 3, 4, and 5Time frame: Up to 3 years
    • AddedMaximum Observed Concentration (Cmax) of AMG 160 - Parts 1, 2, and 3Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
    • AddedTime to Cmax (Tmax) of AMG 160- Parts 1, 2, and 3Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 696 hours)
    • AddedArea Under the Concentration-time Curve (AUC) From Time 0 to Last Quantifiable Concentration (AUClast) of AMG 160- Parts 1, 2, and 3Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))
    • AddedAUC Over the Dosing Interval (AUCtau)- Parts 1, 2, and 3Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
    • AddedTerminal Half-life (t1/2,z) of AMG 160- Parts 1, 2, and 3Time frame: Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
    • RemovedMaximum serum concentration (Cmax) of acapatamabTime frame: Up to 3 years
    • RemovedArea under the concentration-time curve (AUC) over the dosing interval of acapatamabTime frame: Up to 3 years
    • RemovedAccumulation ratio of acapatamabTime frame: Up to 3 years
    • RemovedHalf-life of acapatamabTime frame: Up to 3 years
    • RemovedObjective response (OR)Time frame: Up to 3 years
    • RemovedDuration of response (DOR) (radiographic and PSA)Time frame: Up to 3 years
    • RemovedPercentage of participants experiencing a response based on 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) response evaluationsTime frame: Up to 3 years
    • RemovedChange in time to progression (radiographic and PSA)Time frame: Up to 3 years
    • RemovedProgression-free survival (PFS) (radiographic and PSA)Time frame: Up to 3 years
    • Removed1, 2 and 3-year overall survival (OS)Time frame: Up to 3 years
    • …and 10 more, on the record history on ClinicalTrials.gov ↗
    + 3 other changes: verification date, index terms and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03792841
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 3, 2019
Start date
Feb 5, 2019
Primary completion
Jun 29, 2023
Completion
Jun 29, 2023
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acapatamab

Start the discussion